Zihan Jiang , Xiaoling Yin , Zhonglei Chen , Shixi Liu , Juan Meng , Aiwu Xu
{"title":"Bro p 3, an nsLTP1: The first major allergen identified in Broussonetia papyrifera pollen","authors":"Zihan Jiang , Xiaoling Yin , Zhonglei Chen , Shixi Liu , Juan Meng , Aiwu Xu","doi":"10.1016/j.molimm.2025.04.004","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div><em>Broussonetia papyrifera</em> pollen is an important cause of allergy worldwide, yet its key allergenic components remain unclear. This study aims to identify and characterize the major allergen of <em>B.papyrifera</em> pollen.</div></div><div><h3>Methods</h3><div>Patients with allergic rhinitis (AR) symptoms in <em>B.papyrifera</em> pollen season and positive skin prick test (SPT) to <em>B.papyrifera</em> pollen extract were enrolled. Serum sIgE was measured by ImmunoCAP. The pollen crude extract was immunoblotted with patients’ sera. The major allergen was purified and subjected to mass spectrometry analysis. The cDNA of the allergen was cloned from a pollen cDNA library. The antigenicity of recombinant allergen was measured by ELISA. Overlapping peptides spanning the allergen were synthesized. Type 2 T cell epitopes were screened using patients’ PBMC by IL-4 ELISpot. Cross-reactivity of the allergen was evaluated.</div></div><div><h3>Results</h3><div><em>B. papyrifera</em>-sIgE was confirmed in 194 of 201 patients by ImmunoCAP. Bro p 3 was identified as major allergen by immunoblot. We purified, cloned the cDNA of, and determined the full-protein sequence of Bro p 3, an nsLTP1 with an average mass of 10264 Da. Recombinant Bro p 3 (rBro p 3) exhibited identical antigenicity as natural Bro p 3, with sensitization rates of 74.53 % and 78.89 %, respectively. Peptides Pep 7–21, Pep 10–24 and Pep 13–27 stimulated IL-4 secretion by T cells from 8, 9 and 8 out of 11 patients. Bro p 3-sIgE sensitization was significantly correlated to elevated sIgE of <em>B. papyrifera</em>, <em>Morus alba</em>, <em>Morus. rubra</em>, and <em>Humulus scandens</em>. It was also associated with the concurrence of conjunctivitis and conjunctivitis plus asthma. No IgE binding was found to the other two <em>B.papyrifera</em> nsLTPs. Bro p 3 inhibited the IgE binding to <em>M. alba</em> and <em>H. scandens</em> pollen extracts.</div></div><div><h3>Conclusions</h3><div>We demonstrated that Bro p 3 is the major allergen of <em>B. papyrifera</em> pollen and the first allergen from this species with its full sequence determined. The I<sub>7</sub>-R<sub>27</sub> peptides of Bro p 3 represent its immunodominant type 2 T cell epitopes. Bro p 3 sensitization is relevant to clinical phenotypes and the cross-reactivity between <em>M. alba</em>, <em>H. scandens</em> and <em>B.papyrifera</em> pollen.</div></div>","PeriodicalId":18938,"journal":{"name":"Molecular immunology","volume":"182 ","pages":"Pages 160-170"},"PeriodicalIF":3.2000,"publicationDate":"2025-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular immunology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0161589025001014","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Broussonetia papyrifera pollen is an important cause of allergy worldwide, yet its key allergenic components remain unclear. This study aims to identify and characterize the major allergen of B.papyrifera pollen.
Methods
Patients with allergic rhinitis (AR) symptoms in B.papyrifera pollen season and positive skin prick test (SPT) to B.papyrifera pollen extract were enrolled. Serum sIgE was measured by ImmunoCAP. The pollen crude extract was immunoblotted with patients’ sera. The major allergen was purified and subjected to mass spectrometry analysis. The cDNA of the allergen was cloned from a pollen cDNA library. The antigenicity of recombinant allergen was measured by ELISA. Overlapping peptides spanning the allergen were synthesized. Type 2 T cell epitopes were screened using patients’ PBMC by IL-4 ELISpot. Cross-reactivity of the allergen was evaluated.
Results
B. papyrifera-sIgE was confirmed in 194 of 201 patients by ImmunoCAP. Bro p 3 was identified as major allergen by immunoblot. We purified, cloned the cDNA of, and determined the full-protein sequence of Bro p 3, an nsLTP1 with an average mass of 10264 Da. Recombinant Bro p 3 (rBro p 3) exhibited identical antigenicity as natural Bro p 3, with sensitization rates of 74.53 % and 78.89 %, respectively. Peptides Pep 7–21, Pep 10–24 and Pep 13–27 stimulated IL-4 secretion by T cells from 8, 9 and 8 out of 11 patients. Bro p 3-sIgE sensitization was significantly correlated to elevated sIgE of B. papyrifera, Morus alba, Morus. rubra, and Humulus scandens. It was also associated with the concurrence of conjunctivitis and conjunctivitis plus asthma. No IgE binding was found to the other two B.papyrifera nsLTPs. Bro p 3 inhibited the IgE binding to M. alba and H. scandens pollen extracts.
Conclusions
We demonstrated that Bro p 3 is the major allergen of B. papyrifera pollen and the first allergen from this species with its full sequence determined. The I7-R27 peptides of Bro p 3 represent its immunodominant type 2 T cell epitopes. Bro p 3 sensitization is relevant to clinical phenotypes and the cross-reactivity between M. alba, H. scandens and B.papyrifera pollen.
期刊介绍:
Molecular Immunology publishes original articles, reviews and commentaries on all areas of immunology, with a particular focus on description of cellular, biochemical or genetic mechanisms underlying immunological phenomena. Studies on all model organisms, from invertebrates to humans, are suitable. Examples include, but are not restricted to:
Infection, autoimmunity, transplantation, immunodeficiencies, inflammation and tumor immunology
Mechanisms of induction, regulation and termination of innate and adaptive immunity
Intercellular communication, cooperation and regulation
Intracellular mechanisms of immunity (endocytosis, protein trafficking, pathogen recognition, antigen presentation, etc)
Mechanisms of action of the cells and molecules of the immune system
Structural analysis
Development of the immune system
Comparative immunology and evolution of the immune system
"Omics" studies and bioinformatics
Vaccines, biotechnology and therapeutic manipulation of the immune system (therapeutic antibodies, cytokines, cellular therapies, etc)
Technical developments.